{
    "id": 22176,
    "fullName": "PARP1 Y907F",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "PARP1 Y907F lies within the PARP catalytic domain of the Parp1 protein (UniProt.org). Y907F results in a loss of Parp1 phosphorylation by Met, and impaired DNA damage repair in cell culture (PMID: 26779812).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 142,
        "geneSymbol": "PARP1",
        "terms": [
            "PARP1",
            "ADPRT",
            "ADPRT 1",
            "ADPRT1",
            "ARTD1",
            "pADPRT-1",
            "PARP",
            "PARP-1",
            "PPOL"
        ]
    },
    "variant": "Y907F",
    "createDate": "05/04/2016",
    "updateDate": "05/04/2016",
    "referenceTranscriptCoordinates": {
        "id": 141136,
        "transcript": "NM_001618",
        "gDna": "chr1:g.226364009T>A",
        "cDna": "c.2720A>T",
        "protein": "p.Y907F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6156,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Met expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells overexpressing PARP1 Y907F to Veliparib (ABT-888) in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22733,
                "profileName": "MET dec exp PARP1 Y907F"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6154,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Met expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells overexpressing PARP1 Y907F to Rubraca (rucaparib) in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22733,
                "profileName": "MET dec exp PARP1 Y907F"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 22731,
            "profileName": "PARP1 Y907F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22733,
            "profileName": "MET dec exp PARP1 Y907F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 141136,
            "transcript": "NM_001618",
            "gDna": "chr1:g.226364009T>A",
            "cDna": "c.2720A>T",
            "protein": "p.Y907F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}